The 59th Annual American Society of Hematology (ASH) meeting took place in December 2017, bringing together over 25,000 attendees from around the world. Over 5,000 scientific abstracts were presented, representing the cutting-edge of managing malignant and non-malignant blood diseases.
In collaboration with Professor Stephan Stilgenbauer, we have chosen and reviewed 15 abstracts that represent the forefront of CLL research presented at ASH 2017.
Dr Rhodes and colleagues from the University of Pennsylvania explore the impact of front-line ibrutinib dose reduction and interruption on patient outcomes.
How should patients with relapsed/refractory CLL be treated? New studies are providing insights from real-world data as well as exploring novel combinations and newer treatments.
Do CLL treatments offer similar outcomes to clinical trial data when used in a real-world setting?
Here, we review a group of abstracts that addressed the prognostic impact of specific mutations, minimum residual disease and immune recovery.